Leo Pharma refinances loans and links costs to sustainability targets

Existing loans have been refinanced by Leo Pharma, which has also gained the option of borrowing an additional DKK 1.5bn (USD 230.8m) to execute its growth strategy. A new interest mechanism that links borrowing costs to Leo Pharma's progress toward certain sustainability targets has been implemented.

Photo: Leo Pharma / PR

Leo Pharma has until 2027 to repay loans of more than DKK 11bn (USD 1.7bn) – and has gained access to another unused credit facility of DKK 1.5 (USD 230.8m), it reports in a press release on Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs